Abstract:In the current Research Topic, Critical Complications in Pediatric Oncology and Hematopoietic Cell Transplant, Volume II, there is a continuation of the themes of improving outcomes and strengthening collaboration. This collection contains 21 publications from 195 authors representing 22 different countries on 5 continents (Figure 1). Volume II provides ongoing evidence that the field of pediatric onco-critical care is not going back to the era of the selffulfilling prophecy that critically ill children with cancer have abysmal outcomes rendering use of critical care resources futile.Knowing which HCT patients are at highest risk for requiring ICU care would be very valuable for clinicians. Using data from pediatric oncology patients in the Colorado Sepsis and Treatment Registry, serum lactate within 2 hours of presentation was found to be predictive of clinical deterioration events (OR 1.82, p<0.001), need for ICU admission (OR 1.68, p<0.001) and bacteremia (OR 1.49, p<0.001) [Slatnick et al]. Johnson et al performed a single center retrospective review of pediatric patients who received HCT at their institution between January 2015-December 2020 [Johnson et al]. Risk factors for PICU admission were: 1) younger age; 2) lower weight; 3) inborn error of metabolism as a reason for HCT and 4) use of busulfan conditioning. There was overlap in these results with those found by Zinter et al in a multi-center study merging the Center for International Bone Marrow Transplantation (CIBMTR) and Virtual PICU Performance System (VPS) databases. They also found younger age and inborn errors of metabolism as risk factors for requiring ICU care (17). However, there was disagreement where Zinter found pre-HCT organ dysfunction was associated with increased requirement for ICU admission, whereas Johnson did not. This may represent an improvement over time in managing complex patients during HCT versus differences in study design. A better understand organ dysfunction in these unique patients is imperative for continued improvements in outcomes.Accurate data surrounding the risks and benefits of ICU therapies will lead to better informed decisions regarding PICU interventions. In a retrospective single center study, Schober et al found that admissions for respiratory support (OR 1.04, p=0.04) and dialysis (OR 1.21, p=0.03) increased 6-month mortality compared to other reasons for PICU admission [Schober et al]. In a multi-variate analysis of pediatric oncology patients, hemato-oncology diagnosis, number of failing organs at baseline and unplanned admissions were associated with development of new or progressive multi-organ failure [Soeteman et al]. Data from the Health Facts (Cerner Corporation, Kansas City, MO) database containing 473 pediatric HCT patients found 11% required positive pressure ventilation, 25% received vasopressor medications and 3% received dialysis. Decreased survival was seen in allogeneic transplant (p<0.01), graft versus host disease (p=0.02), infection (p<0.01) and need for ICU therapies (p<0.01) [Olson et al]. Interestingly, survival improved over time for patients who received allogeneic transplants. The improved survival in the later era of the study was associated with decreased infections and increased use of vasopressor agents. The improvement in survival could represent a change in practice due to recent publications addressing the detrimental effects of fluid overload in HCT patients (16,18) with a shift towards earlier use of vasopressors rather than fluid resuscitation.Chimeric antigen receptor therapy, CAR-T, is being used in a growing number of cancers. However, it carries an increased risk for life threatening complications and critical illness. In a multi-center study, Ragoonanan et al compared PICU courses for pediatric ALL patients who were receiving conventional therapy vs those who received tisagenlecleucel [Ragoonanan et al]. They found PICU resource utilization between the 2 groups to be similar. The authors concluded that improved management of complications and need for ICU care should decline over time making CAR-T an important therapy to pursue, potentially beyond high resource settings.Cardenas-Aguirre et al show us that critically ill pediatric oncology patients in resource limited-settings can have PICU outcomes similar to those seen in high income countries [Cardenas-Aguirre et al]. In their dedicated pediatric oncology hospital in Mexico, they describe overall PICU mortality of 6.9% with mortality for unplanned PICU admissions of 9.1%. This is similar to that described in high income countries (19,20) The authors felt their center's low mortality was likely the result of implementing a number of quality improvement practices aimed at earlier recognition of deterioration allowing for earlier interventions.Endotheliopathy has been considered an underlying cause of multiple complications of HCT including sin -Abstract Truncated-

Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor

Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma

A RARE CAUSE OF RECURRENT HAEMOLYTIC ANAEMIA: CARBOPLATIN AND PACLITAXEL-INDUCED AUTOIMMUNE HAEMOLYTIC ANAEMIA

Drug-induced immune hemolytic anemia associated with anti-carboplatin and the first example of anti-paclitaxel

Case report: First case of pemetrexed plus cisplatin-induced immune hemolytic anemia in a patient with lung adenocarcinoma

Immune hemolysis secondary to injection of contrast medium

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia

Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma

Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review

A Rare Case of Methemoglobinemia after Ifosfamide Infusion in a 3-Year-Old Patient Treated for T-ALL

Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy

Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma

Drug-induced immune hemolytic anemia associated with albumin-bound paclitaxel

Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions

A case report of hemophagocytic lymphohistiocytosis induced by toripalimab plus chemoradiotherapy in cervical cancer

Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions

Severe COVID‐19 infection in a child receiving immunotherapy for cancer

Secondary Polycythemia and Non-Islet Cell Tumor-induced Hypoglycemia in Advanced Hepatocellular Carcinoma: A Case Report

Editorial: Critical complications in pediatric oncology and hematopoietic cell transplant, volume II

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung